<p>/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) 是一家致力於靶向治療藥物發現和開發的精準醫學腫瘤公司，今天宣佈，在 2026 年 2 月 26 日，IDEAYA 董事會的薪酬委員會向三名新聘員工授予了總計 346,200 股公司普通股的非合格股票期權。這些股票期權是根據 IDEAYA Biosciences, Inc. 2023 年就業誘導激勵獎勵計劃（2023 Inducement Plan）授予的，作為這些個人與 IDEAYA 簽訂僱傭合同的誘因，符合納斯達克上市規則 5635(c)(4)。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg"/></p>
<p>2023 年誘導計劃專門用於向之前未曾是 IDEAYA 員工的個人授予股權獎勵，或在經過真實的非就業期後，作為這些個人與 IDEAYA 簽訂僱傭合同的誘因，符合納斯達克上市規則 5635(c)(4)。</p>
<p>股票期權的行使價格為每股 31.90 美元，等於授予日 IDEAYA 普通股在納斯達克全球精選市場的收盤價。股票期權的有效期為 10 年，將在四年內逐步歸屬，其中 25% 的期權將在歸屬開始日期的第一週年時歸屬，其餘 75% 的期權將在接下來的三年內按月均勻歸屬。股票期權的歸屬需依賴於員工在每個歸屬日期繼續為 IDEAYA 服務。</p>
<p><strong>關於 IDEAYA Biosciences</strong> IDEAYA 是一家精準醫學腫瘤公司，致力於發現、開發和商業化變革性癌症療法。我們的做法結合了小分子藥物發現、結構生物學和生物信息學的專業知識，以及在識別和驗證轉化生物標誌物方面的強大內部能力，以開發與疾病的遺傳驅動因素相一致的量身定製的潛在首創靶向療法。我們建立了一個深厚的產品候選管道，專注於合成致死性和抗體藥物偶聯物（ADCs），用於分子定義的實體腫瘤適應症。我們的使命是帶來下一波更具選擇性、更有效且深度個性化的精準腫瘤治療，旨在改變疾病進程並改善癌症患者的臨牀結果。</p>
<p><strong>投資者和媒體聯繫</strong></p>
<p>IDEAYA Biosciences</p>
<p>Joshua Bleharski, Ph.D.</p>
<p>首席財務官</p>
<p>investor@ideayabio.com</p>
<p>來源：IDEAYA Biosciences, Inc.</p>

IDYA

<p>IDEAYA Biosciences, Inc.（納斯達克代碼：IDYA）宣佈根據其 2023 年員工誘導激勵獎勵計劃向三名新員工授予 346,200 股非合格股票期權。該授予符合納斯達克上市規則 5635(c)(4)，行使價格為每股 31.90 美元。這些期權將在四年內逐步歸屬，其中 25% 在一年後歸屬，其餘部分按月分期歸屬。IDEAYA 專注於通過精準醫療開發靶向癌症療法</p>

<p>, /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on February 26, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 346,200 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) 是一家致力於靶向治療藥物發現和開發的精準醫學腫瘤公司，今天宣佈，在 2026 年 2 月 26 日，IDEAYA 董事會的薪酬委員會向三名新聘員工授予了總計 346,200 股公司普通股的非合格股票期權。這些股票期權是根據 IDEAYA Biosciences, Inc. 2023 年就業誘導激勵獎勵計劃（2023 Inducement Plan）授予的，作為這些個人與 IDEAYA 簽訂僱傭合同的誘因，符合納斯達克上市規則 5635(c)(4)。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.jpg"/></p>
<p>The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>2023 年誘導計劃專門用於向之前未曾是 IDEAYA 員工的個人授予股權獎勵，或在經過真實的非就業期後，作為這些個人與 IDEAYA 簽訂僱傭合同的誘因，符合納斯達克上市規則 5635(c)(4)。</p>
</div><p>The stock options have an exercise price of $31.90 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.</p>
<div class="lb-trans"><p>股票期權的行使價格為每股 31.90 美元，等於授予日 IDEAYA 普通股在納斯達克全球精選市場的收盤價。股票期權的有效期為 10 年，將在四年內逐步歸屬，其中 25% 的期權將在歸屬開始日期的第一週年時歸屬，其餘 75% 的期權將在接下來的三年內按月均勻歸屬。股票期權的歸屬需依賴於員工在每個歸屬日期繼續為 IDEAYA 服務。</p>
</div><p><strong>About IDEAYA Biosciences</strong> IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.</p>
<div class="lb-trans"><p><strong>關於 IDEAYA Biosciences</strong> IDEAYA 是一家精準醫學腫瘤公司，致力於發現、開發和商業化變革性癌症療法。我們的做法結合了小分子藥物發現、結構生物學和生物信息學的專業知識，以及在識別和驗證轉化生物標誌物方面的強大內部能力，以開發與疾病的遺傳驅動因素相一致的量身定製的潛在首創靶向療法。我們建立了一個深厚的產品候選管道，專注於合成致死性和抗體藥物偶聯物（ADCs），用於分子定義的實體腫瘤適應症。我們的使命是帶來下一波更具選擇性、更有效且深度個性化的精準腫瘤治療，旨在改變疾病進程並改善癌症患者的臨牀結果。</p>
</div><p><strong>Investor and Media Contact</strong></p>
<div class="lb-trans"><p><strong>投資者和媒體聯繫</strong></p>
</div><p>IDEAYA Biosciences</p>
<div class="lb-trans"><p>IDEAYA Biosciences</p>
</div><p>Joshua Bleharski, Ph.D.</p>
<div class="lb-trans"><p>Joshua Bleharski, Ph.D.</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席財務官</p>
</div><p>investor@ideayabio.com</p>
<div class="lb-trans"><p>investor@ideayabio.com</p>
</div><p>SOURCE IDEAYA Biosciences, Inc.</p>
<div class="lb-trans"><p>來源：IDEAYA Biosciences, Inc.</p>
</div>

IDEAYA Biosciences 宣佈根據納斯達克上市規則 5635(c)(4) 授予誘導性股票期權 | IDYA 股票新聞